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Abstract 
  
 Musculoskeletal diseases are among the most common disorders that affect horses, and 
current methods to treat these disorders can be invasive and dependent on the severity of the 
injury. The use of mesenchymal stem cells (MSCs) may provide an effective and non-invasive 
method to treat equine musculoskeletal disorders. An experiment was conducted to analyze the 
safety of treating equine musculoskeletal disorders with an intra-articular injection of a novel 
stem cell product. To measure the safety of the product, the edema elicited by the injection of the 
product was measured using ultrasonographic images. These images were taken before the 
injection and seven and fourteen days after the injection. To measure edema at the three time 
points, three soft tissue measurements were taken for horses affected by tendonitis/desmitis and 
four measurements were taken for horses affected by osteoarthritis at each time point. Edema 
that the intra-articular injection of the stem cells may have elicited was resolved and no longer 
statistically significant within the first week after injection. The transient edema observed 
suggests that the intra-articular injection of the stem cell product is a safe option for treating 
equine musculoskeletal disorders. 
  
 
Introduction 
 
 Musculoskeletal disorders such as osteoarthritis (OA), tendonitis, and desmitis are among 
the most common ailments that affect race, working, and pleasure horses [1-5]. The effects of the 
methods currently used to treat musculoskeletal injuries (e.g., non-steroidal anti-inflammatory 
drugs, tendon splitting, polysulfated glycosaminoglycan, etc.) depend on the severity of the in-
jury and tend to lead to a high rate of reinjury [1,4]. Furthermore, treating these disorders with 
current methods also tends to involve invasive procedures and anesthesia, which present addi-
tional disadvantages [6].  
 Conversely, the use of MSCs is a marginally invasive treatment that has shown promise 
in many different species [2,4,6,7]. The potential for MSCs to differentiate into different tissues 
such as bone, cartilage, and tendon is well known [4,6,8,9]. MSC differentiation is highly 
regulated and dependent on extracellular stimuli such as growth factors and extracellular matrix 
molecules [10]. In a Caprine model, the systemic delivery of bone marrow derived MSCs by 
intra-articular injection utilized extracellular stimuli in injured joints to stimulate tissue 
regeneration [8]. This suggests that intra-articular stem cell injections may have a therapeutic 
affect on OA. In both horses and Sprague Dawley rats, intra-articular MSC injections have also 
been associated with a reduced rate of superficial digital flexor tendon reinjury and a reduced 
degeneration in cruciate ligaments [3,6,11]. The direct intra-articular injection of stem cells has 
shown modest efficacy in equine joint injury models, which may be associated with the ability of 
stem cells to home in on affected tissues [12,13]. While the intra-articular delivery of bone 
marrow derived mesenchymal stem cells shows promise, the harvesting of the cells can be 
invasive. 
 Dental stem cells (DSCs) are easily accessible MSCs derived from dental pulp and they 
provide a potential non-invasive source of pluripotent stem cells [14,15]. DSCs are able to pro-
liferate more rapidly than bone marrow stem cells and DSCs are considered pluripotent because 
they have shown the ability to differentiate into distinct tissues [14,16]. The use of deciduous 
teeth offers a readily available, non-invasive, and reliable source of allogeneic stem cells that 
could be used to treat equine injuries [14,15]. 
 The intra-articular injection of allogeneic stem cells may be a safe and effective option to 
treat equine musculoskeletal injuries [13]. However, several studies have shown mixed results 
about negative effects of allogeneic cell injections such as the presence of edema and 
inflammatory responses [11-13]. In a pilot OA preclinical DSC study using an allogeneic pulp 
cell product (EqPCP), there was swelling of the joint on days 1, 2, 7, and 14 as detailed by joint 
circumference and ultrasonographic image measurements [AL Bertone, unpublished data].  
 The purpose of this study was to determine if edema elicited by the intra-articular 
injection of EqPCP persists up to 7 or 14 days after injection, using the same novel EqPCP as the 
pilot study. We hypothesized that any edema caused by the EqPCP injection would not be statis-
tically significant 7 or 14 days after the intra-articular injection. Edema was not thought to be 
significant one to two weeks after injection because studies on larger scales than the pilot study 
have shown swelling to peak at 48 hours after intra-articular injection of allogeneic stem cells 
[13]. 
 
Materials and Methods 
 
 Ultrasound images were obtained of the 
joints or tendons/ligaments from forty horses 
affected by OA or tendonitis/desmitis, respect-
ively, that met criteria for enrolment in the study 
(lameness score of 2 to 4 on AAEP scale; 
lameness for at least 4 weeks; and one or more 
additional clinical sign of tendonitis, desmitis, or 
OA). The standing ultrasound images were long-
itudinal and obtained directly over the site of 
intra-articular injection. An ACVR Diplomate and 
student selected images that consistently reflected 
the injection site at the affected joint, tendon, or 
ligament from 0, 7, and 14 days after an injection 
of either EqPCP or the carrying vehicle without 
EqPCP.  
 The images containing joints affected by 
OA were analyzed for edema by measuring the 
depth from bone to skin, to represent total soft 
tissue depth; depth from bone to joint capsule margin, to represent the joint fluid; thickness of 
the tendon overlying the joint; and depth of subcutaneous tissue (Fig. 1). The images containing 
tendonitis/desmitis were analyzed for edema by measuring the depth from bone to skin, to 
represent total soft tissue depth; thickness of the injured tendon/ligament; and depth of the 
subcutaneous tissue (Fig. 2). If the same measurement increased between time points (e.g., an 
increase in tendon thickness from 0 to 7 days after injection), it is indicative of an increase in 
edema. To obtain consistent depth measurements of the joint capsule, the measurements at all 
time points began at a constant depth below the bone and a constant thickness between the 
bones. The measurements were carried out through eFilm Workstation1, a program that digitally 
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 Fig. 1. Representative ultrasonographic im-
age of the four measurements ([A] bone to 
skin depth, [B] subcutaneous tissue depth, 
[C] thickness of overlying tendon, [D] bone 
to joint capsule depth starting from [E] a 
constant depth and width) that were taken for 
horses affected by OA. 
measures selected areas on ultrasound images. eFilm Workstation was chosen because it is able 
to automatically adjust the measuring scale based on the depth that the ultrasound image was 
taken at. This automatic adjustment ensures accurate and consistent measurements.
 The measurements were entered into Microsoft Excel and separated into groups of horses 
affected by OA and tendonitis/desmitis. The OA and tendonitis/desmitis groups were then 
separated further based on measurement type (bone 
to skin, tendon/ligament, subcutaneous tissue, etc.). 
Within each measurement type, the data was then 
split into control and treatment groups. In order to 
account for varying bone to skin depths of affected 
areas between horses, changes in depth/thickness 
(between 7 and 0 days after injection and 14 and 0 
days after injection) were converted to percent 
difference changes to standardize the data. Percent 
changes were then added together for each horse to 
yield percent differences in the total measured soft 
tissue depth between days 7 and 0 and days 14 and 
0 (e.g., for a horse affected by OA, percent changes 
in subcutaneous tissue depth, overlying tendon 
width, and joint fluid depth were added together). 
To assess the significance between treatment and 
control groups, a two-factor repeated measure 
analysis of variance (ANOVA) was performed 
using Microsoft Excel. The data met the 
assumptions for two-factor repeated measure 
ANOVA as the Q-Q plots were linear, Levene’s 
tests were not significant, and Mauchly’s tests were 
also not significant. A P-Value of less than 0.05 was 
significant for all tests and analyses. 
 
Results 
 
 Seven and fourteen days after intra-articular injection of EqPCP, no significant dif-
ferences in edema were measured between treatment and control groups at the injection site 
(Table 1). Although not statistically significant differences, in certain measurements, percent 
change increases in tissue depth/thickness were observed for horses that received an injection of 
DSC compared to the control groups in both the OA and tendonitis/desmitis groups (Fig. 3A-F). 
All of the changes in depth/thickness peaked seven days after the intra-articular injection of 
EqPCP. 
 
Table 1. Two Factor Repeated Measure ANOVA Data 
 F Numerator Degrees 
of Freedom 
Denominator Degrees 
of Freedom 
P Value 
Subcutaneous Tissue Depth – Tendonitis/Desmitis Group 
Days After 
Injection 
0.2108 2 54 0.8106 
Fig. 2. Representative ultrasonographic im-
age of the three measurements ([A] bone to 
skin depth, [B] subcutaneous tissue depth, 
[C] thickness of injured tendon/ligament) 
that were taken for horses affected by 
tendonitis/desmitis. 
Treatment/Control 0.3148 1 54 0.5771 
Interaction 0.1743 2 54 0.8405 
Tendon/Ligament Thickness – Tendonitis/Desmitis Group 
Days After 
Injection 
0.0026 2 54 0.9974 
Treatment/Control 12.2575 1 54 0.0009 
Interaction 0.0996 2 54 0.9054 
Total Soft Tissue Depth – Tendonitis/Desmitis Group 
Days After 
Injection 
0.0145 2 54 0.9856 
Treatment/Control 1.4100 1 54 0.2403 
Interaction 0.1118 2 54 0.8945 
Subcutaneous Tissue Depth – Osteoarthritis Group 
Days After 
Injection 
0.0299 2 54 0.9706 
Treatment/Control 4.2884 1 54 0.0432 
Interaction 0.0448 2 54 0.9562 
Overlying Tendon Thickness – Osteoarthritis Group 
Days After 
Injection 
0.6108 2 48 0.5471 
Treatment/Control 11.7625 1 48 0.0013 
Interaction 0.2130 2 48 0.8089 
Joint Fluid Depth – Osteoarthritis Group 
Days After 
Injection 
0.0278 2 54 0.9726 
Treatment/Control 1.2334 1 54 0.2717 
Interaction 0.0050 2 54 0.9950 
Total Soft Tissue Depth – Osteoarthritis Group 
Days After 
Injection 
0.0275 2 54 0.9729 
Treatment/Control 0.4583 1 54 0.5013 
Interaction 0.0285 2 54 0.9719 
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Fig. 3. Change in depth/thickness of tissue at 0, 7, and 14 days after DSC (treatment) and vehicle 
(control) intra-articular injection. (A) Total soft tissue depth of tendonitis/desmitis horses, (B) 
Tendon/Ligament thickness of tendonitis/desmitis horses, (C) Subcutaneous tissue depth of tendon-
itis/desmitis horses, (D) Overlying tendon thickness of OA horses, (E) Joint fluid depth of OA horses, (F) 
Total soft tissue depth of OA horses. 
 
Discussion 
 
 This study showed that the intra-articular injection of EqPCP, a novel DSC product, did 
not cause edema that persists for at least one week after injection. The current study contradicts 
the findings from the pilot preclinical study in which edema persisted over the joint injection site 
for at least 14 days after DSC injection (AL Bertone, unpublished data). The disparity in edema 
measured in the two studies may be a result of the differences in horse enrollment number. The 
small sample size (6 horses) of the pilot study may have lead to a misrepresentation of the edema 
caused by the injection of EqPCP, while the larger size (40 horses) of the current study may 
resolve this issue. 
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 While the results from this study are contradictory to those of the pilot study, they 
confirmed previous findings that edema caused by an intra-articular injection of MSCs is 
transitory [11,13]. It is also expected that a single dose of an anti-inflammatory drug or band-
aging the site of MSC injection after administration would resolve the short-term edema. Both of 
these practices are typical in clinical settings but were not used in the current study. 
 A lack of edema one week after injection is important because it supports the use of 
EqPCP to safely treat OA, tendonitis, and desmitis. By safely treating musculoskeletal disorders, 
this stem cell product may be able to prove its efficacy as a minimally invasive treatment option. 
If effective, this product could find a niche in veterinary medicine as safe technique to treat 
several of the most common equine injuries [1,4,6]. To better understand the safety and potential 
edema at the EqPCP injection site, additional studies are needed to evaluate edema during the 
first week after the injection.  
 In conclusion, the intra-articular DSC injection did not cause edema that persisted for at 
least one week after treatment at the injection site. This result supports previous findings that 
intra-articular MSC injection is a safe option for treating musculoskeletal disorders.
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